Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database

BACKGROUND: High-dose chemotherapy with autologous stem cell rescue (ASCR) is a key component of high-risk neuroblastoma therapy. Resources required to support patients treated with ASCR conditioning regimens [carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel)] have not been direct...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pediatr Blood Cancer
Egile Nagusiak: Desai, Ami V., Seif, Alix E., Li, Yimei, Getz, Kelly, Fisher, Brian T., Huang, Vera, Mante, Adjoa, Aplenc, Richard, Bagatell, Rochelle
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672623/
https://ncbi.nlm.nih.gov/pubmed/26797923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25893
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak